These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32629158)

  • 21. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
    Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
    Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of Cardiotoxicity With Stem Cell-based Strategies.
    Stella Stoter AM; Hirt MN; Stenzig J; Weinberger F
    Clin Ther; 2020 Oct; 42(10):1892-1910. PubMed ID: 32938533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of dual-cardiotoxicity evaluation method based on analysis of field potential and contractile force of human iPSC-derived cardiomyocytes / multielectrode assay platform.
    Lee SG; Kim J; Oh MS; Ryu B; Kang KR; Baek J; Lee JM; Choi SO; Kim CY; Chung HM
    Biochem Biophys Res Commun; 2021 May; 555():67-73. PubMed ID: 33813278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs.
    Sachinidis A
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microengineered systems with iPSC-derived cardiac and hepatic cells to evaluate drug adverse effects.
    Dame K; Ribeiro AJ
    Exp Biol Med (Maywood); 2021 Feb; 246(3):317-331. PubMed ID: 32938227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming.
    Wang H; Sheehan RP; Palmer AC; Everley RA; Boswell SA; Ron-Harel N; Ringel AE; Holton KM; Jacobson CA; Erickson AR; Maliszewski L; Haigis MC; Sorger PK
    Cell Syst; 2019 May; 8(5):412-426.e7. PubMed ID: 31078528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity.
    Sirenko O; Cromwell EF; Crittenden C; Wignall JA; Wright FA; Rusyn I
    Toxicol Appl Pharmacol; 2013 Dec; 273(3):500-7. PubMed ID: 24095675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers.
    Huo J; Kamalakar A; Yang X; Word B; Stockbridge N; Lyn-Cook B; Pang L
    Toxicol Sci; 2017 Mar; 156(1):25-38. PubMed ID: 28031415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prediction of Cardiac Toxicity by Anti-cancer Drugs Using iPSC Cardiomyocytes].
    Yanagida S; Kanda Y
    Yakugaku Zasshi; 2024; 144(3):265-271. PubMed ID: 38432935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes.
    Christidi E; Huang H; Shafaattalab S; Maillet A; Lin E; Huang K; Laksman Z; Davis MK; Tibbits GF; Brunham LR
    Sci Rep; 2020 Jun; 10(1):10363. PubMed ID: 32587261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of extracellular field potential and Ca
    Abi-Gerges N; Pointon A; Oldman KL; Brown MR; Pilling MA; Sefton CE; Garside H; Pollard CE
    J Pharmacol Toxicol Methods; 2017; 83():1-15. PubMed ID: 27622857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interpretation of field potentials measured on a multi electrode array in pharmacological toxicity screening on primary and human pluripotent stem cell-derived cardiomyocytes.
    Tertoolen LGJ; Braam SR; van Meer BJ; Passier R; Mummery CL
    Biochem Biophys Res Commun; 2018 Mar; 497(4):1135-1141. PubMed ID: 28153730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
    Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
    Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiotoxicity Hazard and Risk Characterization of ToxCast Chemicals Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes from Multiple Donors.
    Burnett SD; Blanchette AD; Chiu WA; Rusyn I
    Chem Res Toxicol; 2021 Sep; 34(9):2110-2124. PubMed ID: 34448577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of Drug-Induced Liver Injury in Micropatterned Co-cultures Containing iPSC-Derived Human Hepatocytes.
    Ware BR; Berger DR; Khetani SR
    Toxicol Sci; 2015 Jun; 145(2):252-62. PubMed ID: 25716675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating nonlinear analysis and machine learning for human induced pluripotent stem cell-based drug cardiotoxicity testing.
    Kowalczewski A; Sakolish C; Hoang P; Liu X; Jacquir S; Rusyn I; Ma Z
    J Tissue Eng Regen Med; 2022 Aug; 16(8):732-743. PubMed ID: 35621199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.
    Talbert DR; Doherty KR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Sci; 2015 Jan; 143(1):147-55. PubMed ID: 25304212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterization.
    Burnett SD; Blanchette AD; Chiu WA; Rusyn I
    Expert Opin Drug Metab Toxicol; 2021 Aug; 17(8):887-902. PubMed ID: 33612039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiotoxicity screening: a review of rapid-throughput in vitro approaches.
    Li X; Zhang R; Zhao B; Lossin C; Cao Z
    Arch Toxicol; 2016 Aug; 90(8):1803-16. PubMed ID: 26676948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
    Clements M; Millar V; Williams AS; Kalinka S
    Toxicol Sci; 2015 Nov; 148(1):241-60. PubMed ID: 26259608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.